Recent advances and the potential for clinical use of xenotransplantation

Oktavijan P. Minanov, Silviu Itescu, Robert E. Michler

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The success of allotransplantation has paradoxically led to a shortage in the supply of organs required to meet the increasing demand. Xenografts represent a potentially infinite supply of good quality organs. Recent advances in the understanding of the immunobiology of xenograft rejection has spurred experimental approaches aimed at abrogating or suppressing human xenospecific immune responses. The limited supply of colony-bred nonhuman primates (baboons) makes it highly unlikely that this species will be of widespread use as a donor source. Therefore, the pig has been proposed as a realistic alternative donor. Delineation of the major pig xenoantigens recognized by natural human xenoreactive antibodies has led to the development of strategies aimed at depletion of antibodies or the prevention of their binding to xenogeneic endothelium. Recognition that antibody binding leads to endothelial cell activation and complement-mediated injury has led to the development of genetically modified pigs whose organs are potentially resistant to damage by human complement by virtue of the fact that their endothelial cells express membrane-bound human complement regulatory proteins. Finally, dissection of the relative contributions of humoral and cellular immune responses directed against xenografts from closely or distantly related species has permitted rational recommendations for the administration of immunosuppressive regimens.

Original languageEnglish (US)
Pages (from-to)214-220
Number of pages7
JournalCurrent Opinion in Cardiology
Volume11
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Heterologous Transplantation
Heterografts
Swine
Antibodies
Endothelial Cells
Heterophile Antigens
Papio
Complement Activation
Immunosuppressive Agents
Humoral Immunity
Cellular Immunity
Primates
Endothelium
Dissection
Complement System Proteins
Cell Membrane
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Recent advances and the potential for clinical use of xenotransplantation. / Minanov, Oktavijan P.; Itescu, Silviu; Michler, Robert E.

In: Current Opinion in Cardiology, Vol. 11, No. 2, 1996, p. 214-220.

Research output: Contribution to journalArticle

Minanov, Oktavijan P. ; Itescu, Silviu ; Michler, Robert E. / Recent advances and the potential for clinical use of xenotransplantation. In: Current Opinion in Cardiology. 1996 ; Vol. 11, No. 2. pp. 214-220.
@article{6fe88cb0450d4482afa98930f830ced9,
title = "Recent advances and the potential for clinical use of xenotransplantation",
abstract = "The success of allotransplantation has paradoxically led to a shortage in the supply of organs required to meet the increasing demand. Xenografts represent a potentially infinite supply of good quality organs. Recent advances in the understanding of the immunobiology of xenograft rejection has spurred experimental approaches aimed at abrogating or suppressing human xenospecific immune responses. The limited supply of colony-bred nonhuman primates (baboons) makes it highly unlikely that this species will be of widespread use as a donor source. Therefore, the pig has been proposed as a realistic alternative donor. Delineation of the major pig xenoantigens recognized by natural human xenoreactive antibodies has led to the development of strategies aimed at depletion of antibodies or the prevention of their binding to xenogeneic endothelium. Recognition that antibody binding leads to endothelial cell activation and complement-mediated injury has led to the development of genetically modified pigs whose organs are potentially resistant to damage by human complement by virtue of the fact that their endothelial cells express membrane-bound human complement regulatory proteins. Finally, dissection of the relative contributions of humoral and cellular immune responses directed against xenografts from closely or distantly related species has permitted rational recommendations for the administration of immunosuppressive regimens.",
author = "Minanov, {Oktavijan P.} and Silviu Itescu and Michler, {Robert E.}",
year = "1996",
doi = "10.1097/00001573-199603000-00016",
language = "English (US)",
volume = "11",
pages = "214--220",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Recent advances and the potential for clinical use of xenotransplantation

AU - Minanov, Oktavijan P.

AU - Itescu, Silviu

AU - Michler, Robert E.

PY - 1996

Y1 - 1996

N2 - The success of allotransplantation has paradoxically led to a shortage in the supply of organs required to meet the increasing demand. Xenografts represent a potentially infinite supply of good quality organs. Recent advances in the understanding of the immunobiology of xenograft rejection has spurred experimental approaches aimed at abrogating or suppressing human xenospecific immune responses. The limited supply of colony-bred nonhuman primates (baboons) makes it highly unlikely that this species will be of widespread use as a donor source. Therefore, the pig has been proposed as a realistic alternative donor. Delineation of the major pig xenoantigens recognized by natural human xenoreactive antibodies has led to the development of strategies aimed at depletion of antibodies or the prevention of their binding to xenogeneic endothelium. Recognition that antibody binding leads to endothelial cell activation and complement-mediated injury has led to the development of genetically modified pigs whose organs are potentially resistant to damage by human complement by virtue of the fact that their endothelial cells express membrane-bound human complement regulatory proteins. Finally, dissection of the relative contributions of humoral and cellular immune responses directed against xenografts from closely or distantly related species has permitted rational recommendations for the administration of immunosuppressive regimens.

AB - The success of allotransplantation has paradoxically led to a shortage in the supply of organs required to meet the increasing demand. Xenografts represent a potentially infinite supply of good quality organs. Recent advances in the understanding of the immunobiology of xenograft rejection has spurred experimental approaches aimed at abrogating or suppressing human xenospecific immune responses. The limited supply of colony-bred nonhuman primates (baboons) makes it highly unlikely that this species will be of widespread use as a donor source. Therefore, the pig has been proposed as a realistic alternative donor. Delineation of the major pig xenoantigens recognized by natural human xenoreactive antibodies has led to the development of strategies aimed at depletion of antibodies or the prevention of their binding to xenogeneic endothelium. Recognition that antibody binding leads to endothelial cell activation and complement-mediated injury has led to the development of genetically modified pigs whose organs are potentially resistant to damage by human complement by virtue of the fact that their endothelial cells express membrane-bound human complement regulatory proteins. Finally, dissection of the relative contributions of humoral and cellular immune responses directed against xenografts from closely or distantly related species has permitted rational recommendations for the administration of immunosuppressive regimens.

UR - http://www.scopus.com/inward/record.url?scp=0029940843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029940843&partnerID=8YFLogxK

U2 - 10.1097/00001573-199603000-00016

DO - 10.1097/00001573-199603000-00016

M3 - Article

VL - 11

SP - 214

EP - 220

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 2

ER -